Overview
Dan Vahdat founded Huma in 2011 in London and serves as chief executive officer per Huma’s newsroom and homepage materials. Huma is the operating system for AI in regulated industries — a platform behind leading AI and digital-first health products deployed globally with an AI-driven, software-defined, federated operating model per huma.com reviewed 2026.
Huma’s newsroom states the company began its journey in 2011 when founded in London and has grown into a global healthcare company spanning multiple geographies and operating across four continents.
Role and company
As Founder and CEO, Vahdat leads Huma’s Huma Cloud Platform — core infrastructure connecting disjointed digital health systems into a single federated network with analytics, AI agents, and ML tools turning connected data into action. Huma reports 100+ applications built on HCP, 100+ global clients, and approximately 100 million patients supported globally per homepage metrics.
March 20, 2026 Huma Therapeutics launched Huma Intelligence Scribe powered by NVIDIA AI technology per newsroom — extending Vahdat’s platform into ambient clinical documentation modules.
Background and career context
Huma newsroom identifies Vahdat as founder and CEO since 2011 without a dedicated individual biography page listing prior employers on huma.com reviewed July 2026. His public record is tied to building regulated digital health infrastructure across NHS deployments, pharma clinical trials, and government health programs.
Vahdat appeared in UK Parliament presenting on backing British AI and healthcare — a public policy visibility rare among digital health CEOs outside the United States.
Company-building or leadership context
Under Vahdat, Huma secured multi-condition FDA 510(k) Class II, EU MDR Class IIb, Health Canada Class II, and Saudi FDA Class C regulatory certifications for its configurable SaMD disease management platform per newsroom timeline. Series D financing exceeding $80 million launched Huma Cloud Platform with GenAI integrations per July 2024 newsroom release.
Huma’s enterprise transformation model — discovery, deployment, federated scale-up — reflects Vahdat’s focus on national health system contracts rather than single-hospital SaaS pilots.
Public milestones
2011: Huma founded in London by Dan Vahdat. July 16, 2024: Series D exceeding $80M with GenAI integrations. March 20, 2026: Huma Intelligence Scribe powered by NVIDIA launched. June 5, 2025: Hi Scribe deployed for clinical documentation and billing. Platform supports 4,500+ hospitals and clinics per scribe release disclosures.
Vahdat is founder and CEO across Huma newsroom materials reviewed July 10, 2026.
Why their work matters
Huma under Vahdat demonstrates that regulated disease-agnostic platforms can support diverse modules — RPM, eTriage, clinical trials, ambient scribe — across 70+ countries when core infrastructure handles compliance once. Vahdat’s 2011 founding predates most digital health AI unicorns, giving Huma longitudinal deployment evidence few competitors match.
For healthcare AI readers, Huma is platform infrastructure — partners build on Huma rather than buying point solutions — a model contrasting with best-of-breed ambient AI procurement.
Sources and references
Primary sourcing: Huma newsroom and homepage, reviewed July 10, 2026.
- Huma — Newsroom (huma.com)
- Huma — Homepage (huma.com)
Founded 2011 in London per Huma newsroom About section. Patient and client counts from homepage.
Huma homepage positions the Huma Cloud Platform as governed model of reality unifying clinical, operational, and research data so teams ship mission-critical software fast across care and life sciences — platform thesis Vahdat has pursued since 2011 founding. Three-phase enterprise model (discovery, deployment, federated scale-up) on huma.com gives national health ministries and pharma sponsors structured adoption pathway Vahdat markets against point-solution AI vendors.
Huma newsroom documents multi-condition regulatory certifications across FDA, EU MDR, Health Canada, and Saudi FDA for configurable SaMD platform under Vahdat’s leadership — compliance breadth enabling 70+ country deployments cited on homepage. March 2026 Intelligence Scribe with NVIDIA and June 2025 Samsung biomarker partnership extend Vahdat’s platform into ambient documentation and research endpoints.